Summit Therapeutics (SMMT) Times Interest Earned (2017 - 2024)
Summit Therapeutics' (SMMT) quarterly Times Interest Earned came in at -$8.98 in Q4 2024, up 28.14% YoY from -$7.01 in Q1 2024, and up 62.23% on a QoQ basis from -$23.78 in Q3 2024.
Summit Therapeutics (SMMT) Times Interest Earned (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Times Interest Earned data on file, last reported at -$8.98 in Q4 2024.
- Quarterly Times Interest Earned rose 28.14% year-over-year to -$8.98 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$14.14 (up 59.11% YoY) and the FY2024 annual result came in at -$0.13, up 98.13% from the prior year.
- Times Interest Earned advanced to -$8.98 in Q4 2024, from -$23.78 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$4.46 in Q3 2020 to a low of -$626.78 in Q1 2021.
- A 5-year average of -$64.63 and a median of -$19.44 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 88.1% — and 2024, when it tumbled 324.44%.
- Tracing SMMT's Times Interest Earned over 5 years: stood at -$45.32 in 2020, then gained by 27.88% to -$32.68 in 2021, then surged by 78.61% to -$6.99 in 2022, then plunged by 78.81% to -$12.5 in 2023, then climbed by 28.14% to -$8.98 in 2024.
- The last three Times Interest Earned figures came in at -$8.98 (Q4 2024), -$23.78 (Q3 2024), and -$19.22 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8.98 |
| Sep 30, 2024 | -23.78 |
| Jun 30, 2024 | -19.22 |
| Mar 31, 2024 | -13.58 |
| Dec 31, 2023 | -12.50 |
| Sep 30, 2023 | -7.03 |
| Jun 30, 2023 | -4.53 |
| Mar 31, 2023 | -64.51 |
| Dec 31, 2022 | -6.99 |
| Sep 30, 2022 | -24.48 |
| Jun 30, 2022 | -19.44 |
| Mar 31, 2022 | -74.61 |
| Dec 31, 2021 | -32.68 |
| Jun 30, 2021 | -109.86 |
| Mar 31, 2021 | -626.78 |
| Dec 31, 2020 | -45.32 |
| Sep 30, 2020 | -4.46 |
| Dec 31, 2019 | 175.97 |
| Oct 31, 2019 | -306.13 |
| Jul 31, 2019 | -267.40 |